1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  05/16 12:11:55 pm EDT
130.94 USD   -1.46%
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Higher Ahead of Thursday's Close

01/20/2022 | 03:34pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APTORUM GROUP LIMITED 0.00% 1.03 Delayed Quote.-31.33%
BEIGENE, LTD. 0.42% 132.76 Delayed Quote.-50.96%
NASDAQ COMP. -0.66% 11716.09 Real-time Quote.-24.54%
NOVOCURE LIMITED 5.32% 68.49 Delayed Quote.-13.11%
STAR EQUITY HOLDINGS, INC. 1.05% 0.7701 Delayed Quote.-70.11%
All news about BEIGENE, LTD.
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
05/05Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M
MT
05/05BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 399 M - -
Net income 2022 -1 403 M - -
Net cash 2022 3 140 M - -
P/E ratio 2022 -9,17x
Yield 2022 -
Capitalization 13 709 M 13 709 M -
EV / Sales 2022 7,55x
EV / Sales 2023 5,56x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 132,87 $
Average target price 312,13 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-50.96%13 709
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601